Absstract of: US2023167601A1

A stable aqueous dispersion containing a mixture of an anionic polymer, quaternary ammonium salt, a dispersion agent and water. The dispersing agent is poly (acrylamide-co-acrylic acid) or copolymer of maleic acid and an olefin. The dispersion can be applied to textile materials and nonwoven substrates. Nonwoven substrates, such as polypropylene substrates can be treated with the dispersion to provide a highly active quick killing antimicrobial effect: Log 4 reduction in 5 minutes. This would be useful to deactivate the SARS-CoV-2 virus, which causes Covid-19.

Absstract of: US2023167511A1

Provided herein is a viral RNA detection system, utilizing the RNA-targeting properties of the optimized Cas13d enzyme, CasRx, to detect SARS-CoV-2 RNA, e.g., synthetic SARS-CoV-2 RNA. The system detects novel target sequences conserved within the actively evolving genome, to provide a panel of diagnostic target sites least likely to result in false negatives due to genomic variation. Successful detection of viral RNA through both a fluorescence-based readout assay as well as a rapid paper dipstick lateral flow assay requiring no specialized laboratory equipment was shown. Low viral titers can be detected within minutes following only minutes of sample processing.

Absstract of: US2023167157A1

Immunogenic peptides, polypeptides, protein subunits, nucleic acids encoding the same, compositions and vaccines containing the immunogenic peptides or nucleic acids, and methods of vaccination and/or treatment of SARS-CoV-2 infection. A serological diagnostic assay as well as a use of the serological assay with peptide P3 (SEQ ID NO: 3) to reveal whether a human suspected to be infected or to have been infected by a SARS-CoV-2 virus has generated an anti SARS-CoV-2 protective immunity,

Absstract of: US2023167159A1

A new species of coronavirus, SARS-CoV-2, is the cause of a worldwide pandemic and has resulted in hundreds of thousands of deaths. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions to reduce the severity of, incidence of and transmissibility of SARS-CoV-2.

Absstract of: US2023167166A1

The present invention provides a variety of methods for the identification and/or treatment of subjects that are at risk for developing life-threatening complications of SARS-CoV-2 infection and other infections. Such methods involve determining if a subject has clonal hematopoiesis.

Absstract of: US2023168245A1

The present disclosure provides a lateral flow device, and methods of use of the device, for accurately and rapidly detecting a COVID-19 infection in a subject. The lateral flow device described herein detects in a liquid sample from the subject the presence or absence of neutralizing and non-neutralizing anti-S1 spike antibodies as IgM and IgG types. The anti-S1 antibodies neutralizing antibodies (e.g., both IgM and IgG) can block binding between ACE2 antigen and S1 spike protein which is the basis for the design of the lateral flow device.

Absstract of: US2023168247A1

Methods of detecting SARS-CoV-2 antibodies with improved specificity are described. The methods can include contacting a sample potentially containing SARS-CoV-2 antibodies with a reagent to remove non-anti-SARS-CoV-2 antibodies, such as a reagent comprising an epitope from a nucleocapsid protein or spike protein of a common coronavirus. The methods can include contacting the sample with a mutant SARS-CoV-2 nucleocapsid protein or spike protein comprising a reduced number of common coronavirus epitopes. The methods can involve comparing results from an immunoassay performed with a SARS-CoV-2 protein to results obtained from immunoassays performed with analogous protein from one or more common coronaviruses.

Absstract of: AU2021375281A1

The present invention relates to pharmaceutical compositions comprising an mRNA encoding an IFN-λ polypeptide for use in treating a viral-induced disorder, preferably a viral-induced respiratory disorder, such as COVID-19.

Absstract of: AU2021364100A1

Lateral flow assay (LFA) devices for detecting whether SARS-CoV-2 nucleocapsid protein is present in a sample are provided. Aspects of the LFA devices include: a sample receiving region; a conjugate region downstream from the sample receiving region that includes test particulate labels made up of label particles conjugated to first and second specific binding members that specifically bind to the SARS-CoV-2 nucleocapsid protein; and a detection region downstream from the conjugate region which includes an immobilized capture specific binding member that specifically binds to the SARS-CoV-2 nucleocapsid protein. Also provided are methods of using the LFA devices, as well as readers, systems and kits for use in the same.

Absstract of: US2023168249A1

Disclosed herein are recombinant antibodies or the fragment thereof for detecting severe acute respiratory syndrome coronavirus (SARS-CoV). According to some embodiments, the SARS-CoV is SARS-CoV-1. According to some alternative embodiments, the SARS-CoV is SARS-CoV-2. Also disclosed herein are a kit comprising the recombinant antibodies, and a method for diagnosing the infection of SARS-CoV by using the recombinant antibody or the kit.

Absstract of: AU2021363921A1

The present invention provides a new component that is useful as a SARS-CoV-2 vaccine antigen that uses as a target a receptor binding domain of SARS-CoV-2. This fusion protein includes hemagglutinin and a receptor binding domain of SARS-CoV-2. This vaccine includes said fusion protein.

Absstract of: AU2021355767A1

This invention pertains to biotechnology, more specifically to the field of human health. What is described in particular are covalent conjugates of the SARS-CoV-2 receptor binding domain with a carrier protein, the method used to obtain the conjugates, and the vaccine compositions that contain them. The vaccine compositions described in the present invention are useful for the prevention of the SARS-CoV-2 infection as they induce a strong response of neutralizing antibodies.

Absstract of: AU2021351255A1

The present invention provides a SARS-CoV-2 protein-derived epitope peptide capable of inducing cytotoxic T cells. The present invention also provides: a polynucleotide encoding the peptide; an antigen-presenting cell presenting the peptide; a cytotoxic T cell (CTL) targeting the peptide; and a method for inducing the antigen-presenting cell or the CTL. The present invention further provides a composition or a pharmaceutical composition containing the foregoing as an active ingredient. Furthermore, the present invention provides a method for treating and/or preventing the corona virus infectious disease, and/or a method for suppressing the aggravation of the disease, using the peptide, the polynucleotide, the antigen-presenting cells, the cytotoxic T cells, or the pharmaceutical composition according to the present invention. Also provided is a method for an inducing an immune response to coronavirus infection.

Absstract of: WO2023094885A2

Immunogenic peptides, polypeptides, protein subunits, nucleic acids encoding the same, compositions and vaccines containing the immunogenic peptides or nucleic acids, and methods of vaccination and/or treatment of SARS-CoV-2 infection. A serological diagnostic assay as well as a use of the serological assay with peptide P3 (SEQ ID NO: 3) to reveal whether a human suspected to be infected or to have been infected by a SARS-CoV-2 virus has generated an anti SARS-CoV-2 protective immunity.

Absstract of: WO2023096476A1

In the field of food-processing methods, the invention relates to a hybrid solar dryer with forced convection and for thin-layer drying, as used in dryers for the food processing industry. The innovation in this novel dryer is to have a closed circuit of hot air between the solar panels and the pair of drying chambers with an opening for replenishing air when needed. The capacity of this dryer is 1 metric quintal as it houses 10 racks of 10 kg each in each chamber. Only five racks are equipped with scales for tracking the weight of the product without it being weighed outside and absorbing moisture. The aerothermal data inside the chamber are monitored (T° and humidity) by an automatic device for real-time recording of data in CSV format (Excel) via a Wi-Fi network. The two paired chambers are equipped with a UV lamp having sufficient capacity to disinfect the entire surface of the dryer and the products to be dried (1 quintal).

Absstract of: WO2023094980A1

The present disclosure provides human monoclonal antibodies that have potent neutralizing activity against SARS-CoV-2. The present disclosure also provides prevention methods, treatment methods, compositions, pharmaceutical compositions, and vaccine compositions that comprise or utilize the human monoclonal antibodies provided herein.

Absstract of: WO2023094571A1

The present invention relates a combination product comprising a fusion protein of ACE2 with an Fc part of human Ig and an ACE2 inhibitor as well as to the medical use of this combination product, in particular in the prevention or treatment of infections with coronaviruses such as SARS-CoV-2. The present invention also relates to the stabilization of comprising a fusion protein of ACE2 with an Fc part of human Ig with an ACE2 inhibitor..

Absstract of: WO2023094595A1

A propagation-defective, replication-competent RNA replicon derived from the SARS-CoV-2 coronavirus that comprises a polynucleotide sequence SEQ_ID 2 or a variant of SEQ_ID 2 having at least 80 % identity, more preferably 85% identity, even more preferably at least 90 % identity, and even more preferably 91 % or 92 % or 93 % or 94 % or 95 % or 96 % or 97 % or 98 % or even up to 99 % identity with respect to the SEQ_ID 2 polynucleotide sequence, wherein the variant of SEQ_ID2 does not comprise sequences suitable for expressing an ORF8 protein, wherein the ORF8 protein is encoded by a gene having at least 80% identity to the sequence of SEQ_ID36, methods of preparation thereof and the use in vaccine compositions.

Absstract of: WO2023094507A1

The present invention relates to fusion proteins of ACE2 with IgG Fc and the medical use of these fusion proteins, in particular in the prevention or treatment of infections with coronaviruses such as SARS-CoV-2, as well as methods of producing them.

Absstract of: WO2023096896A2

This application relates to methods of treating and/or preventing a coronavirus infection in a subject in need thereof, and treating cardiac injury in said subjects.

Absstract of: WO2022020810A1

There are provided herein, inter alia, complexes, compositions and methods for a vaccine for COVID-19. The cell-penetrating complexes provided herein may include a nucleic acid non- covalently bound to a cationic amphipathic polymer, the cationic amphipathic polymer including a pH-sensitive immolation domain. The cell-penetrating complexes provided herein are, inter alia, useful in vaccines, wherein the vaccine includes a ribonucleic acid including a sequence encoding a viral protein, a nucleic acid adjuvant and a cationic amphipathic polymer provided herein including embodiments thereof.

Absstract of: EP4186922A1

The present invention relates to a binding molecule having neutralizing activity against the coronavirus superfamily. More specifically, the binding molecule of the present invention has excellent binding affinity and excellent neutralizing efficacy against various coronavirus species that may infect humans, including not only wild-type SARS-coronavirus-2 (SARS-CoV-2) and mutant viruses that may occur in the future, but also SARS-coronavirus-1 (SARS-CoV-1), Middle East respiratory syndrome coronavirus (MERS-CoV), etc., which infect humans, causing fatal diseases. Thus, the binding molecule is very useful for the diagnosis, prevention or treatment of diseases caused by coronaviruses.

Absstract of: EP4186497A1

The invention relates to the use of the solubilized Alpha Lipoic Acid, solubilized Epigallocatechin 3-gallate, and solubilized Curcumin in combination as (a) therapeutic agent(s) for the prophylaxis and/or treatment of arthritis including, without limitation, fibrotic disease, inflammatory disease, neurodegenerative disease, autoimmune disease, or heart and vascular disease as a consequence of arthritic pathophysiology, and viral infections including SARS-CoV-2 infections.The invention further relates to the use of the mentioned solubilized therapeutic agent(s) for for oral administration, and for inhalative administration.

Absstract of: EP4186500A1

The present invention relates to MEK inhibitors for use in a method of treatment or prevention of a disease caused by a coronavirus in a human subject, wherein the disease comprises a long COVID syndrome. Also provided are compositions comprising such inhibitors for use in the treatment of a corona virus infection, such as COVID-19.

Absstract of: KR20230074664A

코로나19 혹은 신종코로나바이러스감염증, COVID-19 의 경우 새로운 문화를 창조할 정도로 이 바이러스는 전 인류적인 문제를 일으켰으며, 이로 인해 골머리를 앓는 지도자들과 과학자들이 많았다. 비대면 문화를 생성시켜서 수많은 일을 디지털화 하는데 일조하기도 했지만, 2023년 기준 최소 600만명의 소중한 생명을 앗아간 치명적인 바이러스다. 코로나19 변이 중에는 alpha 변이, beta 변이, gamma 변이, delta 변이, mu 변이부터 오미크론 및 하위, 변종 변이까지 끊임없는 변이종이 나오는 + sense RNA 바이러스이다. 본 발명으로 해결하려는 과제는 코로나19용 전사 방지 및 자동 소멸 촉진을 위한 플랫폼이다. 이 COVID는 굵고 길게 간다. SARS 보다 GC content 가 5% 낮고, RNA DNA 바이러스 통틀어 최하위를 기록한다. 유전체가 너무 길어 잘게 쪼개서 2차구조를 보고 있는데, 10동강을 내야 하고, 정확한 자유에너지 분석이 안된다. 이를 대응하기 위한 조성물 발명이다.